Navigation Links
Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
Date:11/12/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Nov. 12 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced positive final results from its pilot GHRH Phase II study. Within only 4 weeks of treatment, Akela GHRH induced a highly significant stimulation of endogenous growth hormone (GH) secretion and a marked increase of circulating insulin-like growth factor (IGF-1) as compared to placebo in patients with chronic kidney disease. These endocrine effects were associated with a significant increase in Fat Free Mass (FFM), and concomitant reduction in Fat Mass (FM) when measured by DEXA scan and bioelectrical impedance (BIA). As we reported in July 2007, the study did not reveal significant changes between treatment groups in total body protein turnover. Total body protein turnover, as measured by 13C leucine kinetics, was normal in both treatment groups already at baseline, most probably reflecting adaptative changes of metabolic balance in the chronic disease state.

ABOUT THE STUDY:

The study was conducted at 3 European sites. It was designed to evaluate the clinical potential of GHRH analogue (AKL-0707) administration in improving body composition, nutritional and metabolic parameters in malnourished patients with stage IV or pre-dialytic stage V chronic kidney disease (CKD). Malnutrition was defined by either serum albumin <40 g/l, body mass index (BMI) <23, or a greater than 5% loss of body weight in the last 6 months.

Twenty-eight patients were randomized to either GHRH analogue subcutaneously (sc.) (13 patients) or placebo sc. (15 patients). Twenty-six subjects completed the study as planned. The mean age was 61.8 and 63.4 in the GHRH analogue and placebo groups, respectively. The treatment was administered twice daily (AM & PM) for 28 days, at a dose of approximately 15 (micro)g/kg body weight (BW).

The measurement of protein turnover as assessed by 13C-leucine kinetics was selected as the primary parameter to monitor the trend in protein metabolism as published clinical data suggested an improvement in lean body mass was not to be expected within one month of treatment. In addition, the study focused on the effect of GHRH analogue on endogenous 24-hour growth hormone (GH) secretion, circulating total insulin-like growth factor (IGF-1) and its binding proteins IGFBP-1 and IGFBP-3, fat-free mass (FFM) and fat mass (FM) as assessed by Dual X-ray absorptiometry (DEXA) and bioimpedance (BIA), biochemical parameters of nutritional and metabolic states, as well as safety and tolerability.

FINDINGS

In the Intention to Treat (ITT) population, a 4-week treatment with GHRH analogue produced the following statistically significant (p<0.05) changes in comparison to placebo:

- A 393% increase in mean 24-hour integrated GH secretion rate as

compared to a 22% increase in the placebo group (24h AUC). GHRH

analogue treatment did not affect the natural pulsatile rhythm of

endogenous GH secretion.

- A 104% increase in median total circulating IGF-1, mean 26.7% decrease

in IGFBP-1 and no significant change in IGFBP3 concentration,

indicating an increase in the free circulating IGF-1 available to

tissues, as compared to 3.5% increase in IGF-1 and 2.4% increase in

IGFBP concentrations in the placebo group.

- A marked improvement in the global nutritional state as assessed by the

physicians. In the GHRH group, 6 out of 9 patients rated malnourished

at baseline were classified well-nourished after 4 weeks of therapy. By

contrast, the nutritional assessment remained unchanged in each of

11 patients classified malnourished in the placebo group.

- An increase from baseline in FFM (median 3.3 kg by BIA and 1.6 kg by

DEXA) and a concomitant decrease in FM (median 1.8 kg by BIA and 0.4 kg

by DEXA). These changes were observed in all but one (11/12) patients

in the GHRH analogue group on day 28, and contrasted with a decrease in

FFM and an increase in FM in the placebo arm. The increase in FFM was

most pronounced in the leg and trunk regions.

- A GH-mediated increase in median extracellular water (ECW) by 1.9 L and

intracellular water (ICW) by 1.2 L. While ratio of median ECW/ICW (1.2)

on day 28 remained unchanged, indicating no negative impact in terms of

extracellular fluid retention.

- A significant increase in fasting insulin levels, as typically observed

with human growth hormone treatment. The change in fasting insulin was

not associated with adverse changes in fasting glucose or glycosylated

hemoglobin levels, indicating that the GHRH analogue treatment did not

adversely affect the glucose balance of the patients.

There were no statistically or clinically significant differences between the treatment groups in terms of safety assessments. There were no human anti-GHRH antibodies detected in any of the patients.

There were altogether 128 on-treatment adverse events (AE) reported by 26 subjects: 70 with GHRH analogue and 58 with placebo. Only one AE, injection site bruising, was classified as definitely caused by GHRH analogue treatment. Four serious adverse events (SAE) were reported, 3 in the placebo and one in the GHRH analogue groups. None of the SAEs were considered to be related to the study medication.

"The positive final results of our GHRH Phase II clinical trial confirm the substantial therapeutic potential of GHRH analogue, and clearly justify pursuing further clinical studies in not only chronic renal failure but also in other wasting diseases such as severe COPD and HIV-infection associated wasting." said Dr. Halvor Jaeger, Chief Executive Officer of Akela Pharma Inc.

THE ISSUER HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE SEC (FILE NO. 333-146684) FOR AN OFFERING OF ITS SECURITIES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER DOCUMENTS THE ISSUER HAS FILED WITH THE SEC FOR MORE COMPLETE INFORMATION ABOUT THE ISSUER AND THIS OFFERING. YOU MAY GET THESE DOCUMENTS FOR FREE BY VISITING EDGAR ON THE SEC WEB SITE AT http://WWW.SEC.GOV. ALTERNATIVELY, THE ISSUER, ANY UNDERWRITER OR ANY DEALER PARTICIPATING IN THE OFFERING WILL ARRANGE TO SEND YOU THE PROSPECTUS IF YOU REQUEST IT BY CONTACTING OPPENHEIMER AND CO. INC. AT 125 BROAD STREET, 16TH FLOOR, NEW YORK, NEW YORK 10004, ATTENTION: SYNDICATE DEPARTMENT, OR BY PHONE AT (212) 825 4341

Conference call information:

Akela will host a conference call at 11.00 am, on Monday November 12, 2007. Interested parties may also access the conference call by webcast at http://www.akelapharma.com.

The telephone numbers to access the conference call are 416-644-3426 or 1-800-594-3615. A replay of the call will be available until Monday November 19, 2007. The telephone numbers to access the replay are 416-640-1917 and 1-877-289-8525 with code number 21253359#.

About Malnutrition in chronic renal failure (CRF)

CRF is a gradual and progressive loss of the ability of the kidneys to excrete wastes, concentrate urine and conserve electrolytes. CRF usually develops over years as the kidney structures are slowly damaged. Advanced CRF is characterized by anorexia, malnutrition, wasting, latent inflammation, accelerated atherosclerosis and a state of resistance to multiple endogenous hormones. Resistance to endogenous growth hormone is believed to contribute to tissue catabolism, but can be overcome by administration of exogenous growth hormone at pharmacological doses. Administration of AKL-0707 may stimulate endogenous growth hormone release sufficiently to reverse loss of muscle mass particularly in pre-end stage CRF patients, in whom resistance mechanisms are not as marked yet while many patients are already malnourished.

About Akela's GHRH (AKL-0707)

Akela's proprietary 29 amino-acid peptide analogue of GHRH is designed to stimulate growth hormone secretion in patients. Positive results from its previous Phase I/II trial showed that after administration of AKL-0707, a rapid and very significant increase in the levels of growth hormones occurred at all dosage levels without significant adverse events.

About Akela Pharma Inc.

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

THIS NEWS RELEASE CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS THAT REFLECT THE CURRENT VIEWS AND/OR EXPECTATIONS OF AKELA PHARMA INC. WITH RESPECT TO ITS PERFORMANCE, BUSINESS AND FUTURE EVENTS. SUCH STATEMENTS ARE SUBJECT TO A NUMBER OF RISKS, UNCERTAINTIES AND ASSUMPTIONS. ACTUAL RESULTS AND EVENTS MAY VARY SIGNIFICANTLY.


'/>"/>
SOURCE Akela Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. Akela Pharma Inc. Completes Share Consolidation
3. AKELA Pharma Inc. announces U.S. public offering and proposed listing
4. Akela Pharma reports results for third quarter of fiscal 2007
5. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
6. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... , ... December 08, 2016 , ... With the increasing ... the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about the ... the dental implant and prosthetic market in the U.S. is projected to reach $6.4 ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... Bodycad announced it has been awarded ... reproducibility and speed for 3D constructs via MRI ... orthopaedic applications. These patents are critical to the ... based on each patient,s distinct anatomy. ... the world,s first suite of orthopaedic CAD/CAM software. ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: